ArticleInternational journal of cancer2026
Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.
Jinxia Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.